TTrialPathMatch Me to Trials
← Back to trials
RecruitingNon-Small Cell Lung Cancer (NSCLC)

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Eligible age

18+ yrs

Accepts

All genders

Locations

19 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.

Sponsor: Bristol-Myers Squibb

You may qualify if…

  • ✓ Participants must have a histologically or cytologically confirmed diagnosis of Non-Small Cell Lung Cancer (NSCLC) (squamous and nonsquamous) with Stage IIIB/IIIC or Stage IV disease.
  • ✓ Participants must have a programmed death ligand-1 (PD-L1) expression ≥ 50%.
  • ✓ Participants must have measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
  • ✓ Participants must have no prior systemic anti-tumor therapy for locally advanced or metastatic NSCLC.
  • ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.

You may not qualify if…

  • ✕ Participants must not have any documented actionable genomic alteration (AGA) for which first-line (1L) approved therapies are indicated.
  • ✕ Participants must not have any symptomatic untreated central nervous system (CNS) metastases, leptomeningeal metastases (carcinomatous meningitis) or spinal cord compression.
  • ✕ Participants must not have any significant cardiovascular impairment as evidenced by uncontrolled hypertension (despite optimal medical treatment), congestive heart failure, active coronary disease (within 6 months prior to randomization), ventricular arrhythmias, or major thrombotic or embolic events or major hemorrhagic events (within 6 months prior to randomization), or significant risk of pulmonary hemorrhage.
  • ✕ Participants must not an active autoimmune disease.
  • ✕ Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's recruiting

Alabama

Daphne

Arizona

Bullhead City · Glendale

California

Beverly Hills · Fountain Valley · Los Alamitos · Los Angeles …

Colorado

Lakewood

Florida

Clermont · Coral Springs · Hialeah · Tamarac

Georgia

Athens · Augusta · Marietta

Illinois

Urbana

Missouri

Columbia

New York

Laurelton · New York · Westbury

North Carolina

Winston-Salem

Ohio

Cincinnati

Source: ClinicalTrials.gov · NCT07361510 · last updated 2026-10-23

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in · TrialPath